Could a 12-week steroid course be enough for kidney disease?

NCT ID NCT07151456

Not yet recruiting Disease control Sponsor: First Affiliated Hospital of Wenzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study compares a 12-week steroid course to the standard 24-week course for adults with steroid-sensitive nephrotic syndrome, a kidney condition that causes protein leakage and swelling. Researchers want to see if the shorter treatment can keep the disease from coming back just as well. About 224 adults will take part, receiving either the short or long regimen of prednisolone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Prednisolone (a steroid drug)
What this could lead to: If successful, this could show that a shorter steroid course is enough to control the disease, reducing side effects from long-term use.
What could go wrong: This is a Phase 4 trial, but it is not yet recruiting. The shorter course may lead to more relapses, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC NEPHROTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic nephrotic syndrome idiopathic steroid-sensitive nephrotic syndrome lipoid nephrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC NEPHROTIC SYNDROME

Contacts and locations

Locations

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, 325000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.